SG170041A1 - Methods for cancer therapy and stem cell modulation - Google Patents

Methods for cancer therapy and stem cell modulation

Info

Publication number
SG170041A1
SG170041A1 SG201101385-1A SG2011013851A SG170041A1 SG 170041 A1 SG170041 A1 SG 170041A1 SG 2011013851 A SG2011013851 A SG 2011013851A SG 170041 A1 SG170041 A1 SG 170041A1
Authority
SG
Singapore
Prior art keywords
methods
stem cell
cancer therapy
cell modulation
general formula
Prior art date
Application number
SG201101385-1A
Other languages
English (en)
Inventor
Qiang Yu
Jing Tan
Xiao Jing Yang
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG170041A1 publication Critical patent/SG170041A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG201101385-1A 2006-03-02 2006-11-15 Methods for cancer therapy and stem cell modulation SG170041A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77853206P 2006-03-02 2006-03-02

Publications (1)

Publication Number Publication Date
SG170041A1 true SG170041A1 (en) 2011-04-29

Family

ID=38459334

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201101385-1A SG170041A1 (en) 2006-03-02 2006-11-15 Methods for cancer therapy and stem cell modulation

Country Status (7)

Country Link
US (2) US8058258B2 (https=)
EP (2) EP1993553B1 (https=)
JP (3) JP5468782B2 (https=)
AU (1) AU2006339445A1 (https=)
SG (1) SG170041A1 (https=)
TW (1) TW200812590A (https=)
WO (1) WO2007100304A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101909630A (zh) 2007-11-02 2010-12-08 新加坡科技研究局 预防和治疗肿瘤的方法和化合物
WO2010027935A1 (en) * 2008-09-08 2010-03-11 Merck Sharp & Dohme Corp. Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
CN102369204A (zh) * 2008-09-26 2012-03-07 新加坡科技研究局 3-脱氮瓶菌素衍生物
WO2010111712A2 (en) * 2009-03-27 2010-09-30 Cold Spring Harbor Laboratory Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
SG180031A1 (en) * 2010-10-15 2012-05-30 Agency Science Tech & Res Combination treatment of cancer
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
CA2819620A1 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
US8580762B2 (en) 2010-12-03 2013-11-12 Epizyme, Inc. Substituted purine and 7-deazapurine compounds
CA2831403A1 (en) * 2011-05-19 2012-11-22 Glax L.L.C. Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
WO2013036846A2 (en) * 2011-09-09 2013-03-14 Koronis Pharmaceuticals, Incorporated N4 derivatives of deoxycytidine prodrugs
US20150038548A1 (en) * 2012-07-09 2015-02-05 Metheor Therapeutics Corporation Oligonucleotide inhibitors of dna methyltransferases and their use in treating diseases
US20150284422A1 (en) 2012-08-10 2015-10-08 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
US9597348B2 (en) 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
EP2908913B1 (en) 2012-10-17 2018-10-03 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
US20160010059A1 (en) * 2013-03-06 2016-01-14 The Regents Of The University Of California EXPANSION OF HEMATOPOIETIC PROGENITOR CELLS BY HISTONE METHYLTRANSFERASE G9a INHIBITION
US9738679B2 (en) 2013-03-15 2017-08-22 Epizyme, Inc. Methods of synthesizing substituted purine compounds
WO2016022563A1 (en) 2014-08-04 2016-02-11 Auburn University Enantiomers of the 1',6'-isomer of neplanocin a
WO2016149299A1 (en) * 2015-03-16 2016-09-22 Epinova Therapeutics Corp. Therapeutic compounds that suppress protein arginine methyltransferase activity for reducing tumor cell proliferation
WO2020055663A1 (en) * 2018-09-11 2020-03-19 The Texas A&M University System L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2)
WO2020057107A1 (zh) * 2018-09-17 2020-03-26 诺未科技（北京）有限公司 一种组合物及其用途
WO2023249714A1 (en) * 2022-06-24 2023-12-28 Memorial Sloan-Kettering Cancer Center Therapeutic compositions and methods for activating double stranded rna response in cancer patients via dnmt1 targeted therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510260A (en) * 1893-12-05 Electric-arc-lighting system
US4975434A (en) * 1986-05-27 1990-12-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral and anticancer cyclopentenyl cytosine
US4968690A (en) 1986-05-27 1990-11-06 United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it
JPH04327587A (ja) 1991-04-26 1992-11-17 Asahi Chem Ind Co Ltd ６’−ｃ−アルキル−３−デアザネプラノシンａ誘導体、その製造法およびその用途
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
JP2002507404A (ja) * 1998-03-27 2002-03-12 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド−抗ＨＥＲ−２抗体相乗作用
SE517975C2 (sv) 2000-05-30 2002-08-13 Power Ab C Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion
US20050191618A1 (en) 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
ES2378524T3 (es) 2002-09-13 2012-04-13 The Board Of Trustees Of The Leland Stanford Junior University Célula progenitora de megacariocitos de mamífero
AU2003295444A1 (en) 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
US20050245559A1 (en) 2004-01-23 2005-11-03 Koul Hari K Treatment and prevention of prostate cancer
WO2005105136A1 (en) 2004-04-27 2005-11-10 University Of South Florida Nanogene therapy for cell proliferation disorders
ATE511859T1 (de) 2004-07-20 2011-06-15 Schering Corp Apoptoseinduktion in toll-artige rezeptoren exprimierenden tumorzellen

Also Published As

Publication number Publication date
EP2522352A1 (en) 2012-11-14
JP2013121974A (ja) 2013-06-20
US8211869B2 (en) 2012-07-03
JP5468782B2 (ja) 2014-04-09
EP1993553B1 (en) 2013-05-08
JP2009528345A (ja) 2009-08-06
WO2007100304A1 (en) 2007-09-07
JP2014028853A (ja) 2014-02-13
TW200812590A (en) 2008-03-16
US20120077841A1 (en) 2012-03-29
US20100075915A1 (en) 2010-03-25
EP1993553A1 (en) 2008-11-26
US8058258B2 (en) 2011-11-15
JP5902138B2 (ja) 2016-04-13
AU2006339445A1 (en) 2007-09-07
EP1993553A4 (en) 2010-07-28
EP2522352B1 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
SG170041A1 (en) Methods for cancer therapy and stem cell modulation
MX2011006290A (es) Compuestos de aza-azuleno.
MX2010005095A (es) Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion.
PH12013501871A1 (en) Cyclopropylamines as lsd1 inhibitors
IL184678A0 (en) Proteasome inhibitors and methods of using the same
MX2009011878A (es) Compuestos antagonistas de acido ribonucleico para la modulacion de beta-catenina.
IL173722A0 (en) Proteasome inhibitors and methods of using the same
MX2009012623A (es) Moduladores de cinasa heterociclicos.
GEP20156310B (en) Methods of using c-met modulators
TN2012000280A1 (en) Methods of administering pirfenidone therapy
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
WO2012037155A3 (en) Tyrosine kinase inhibitors
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
PH12014501639B1 (en) Pharmaceutical compositions and methods
MX2012000949A (es) Terapias de combinacion con moduladores de ck2.
MX2013008212A (es) Derivados de 7-azaindol.
EP4375279A3 (en) Cot modulators and methods of use thereof
MX2015001551A (es) Compuestos y composiciones activadoras de enzima.
MX2011011431A (es) Composicion para el tratamiento de cancer de prostata.
IL207310A0 (en) Vaccine compositions
MX2012010212A (es) Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer.
WO2007092944A8 (en) Compositions and methods involving gene therapy and proteasome modulation
WO2012087115A8 (en) Cancer targeting using carbonic anhydrase isoform ix inhibitors
MY162518A (en) Proteasome inhibitors and methods of using the same
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.